➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Mallinckrodt
Dow
McKesson
Colorcon

Last Updated: August 10, 2020

DrugPatentWatch Database Preview

Litigation Details for In re Lantus Direct Purchaser Antitrust Litigation (D. Mass. 2016)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

In re Lantus Direct Purchaser Antitrust Litigation (D. Mass. 2016)

Docket   Start Trial Date Filed 2016-12-30
Court District Court, D. Massachusetts Date Terminated 2018-10-24
Cause 15:1 Antitrust Litigation Assigned To Judith G. Dein
Jury Demand Plaintiff Referred To
Parties FWK HOLDINGS LLC
Patents 7,291,132; 7,476,652; 7,713,930; 7,918,833; 8,512,297; 8,556,864; 8,603,044; 8,679,069; 8,992,486; 9,011,391; 9,233,211; 9,408,979; 9,526,844; 9,533,105; 9,561,331; 9,604,008; 9,604,009; 9,610,409; 9,623,189; 9,775,954; 9,827,379
Attorneys Laura Diss Gradel
Firms Jones Day
Link to Docket External link to docket
Small Molecule Drugs cited in In re Lantus Direct Purchaser Antitrust Litigation
The small molecule drugs covered by the patents cited in this case are   Start Trial and   Start Trial .
Biologic Drugs cited in In re Lantus Direct Purchaser Antitrust Litigation

Details for In re Lantus Direct Purchaser Antitrust Litigation (D. Mass. 2016)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 1 13, 2009, the PTO issued U.S. Patent No. 7,476,652 (“the ’652 patent”), entitled “Acidic Insulin Preparations…ingredient) patents, drug product (formulation and composition) patents, and method of use patents.” Abbreviated… In the ’930 patent, which has the same examples as the ’652 patent, a different patent examiner allowed…polysorbate vial formulation patents, Sanofi listed the ’652 patent and the ’930 patent to be identified in the…044 patents are herein called the “DCA injector pen patents.” All of the DCA injector pen patents are External link to document
0000-00-00 40 864 patent was improperly listed in the Orange Book. 2 These are U.S. Patent No. 7,476,652 (“the…the ‘652 patent”), and U.S. Patent No. 7,713,930 (“the ‘930 patent”). 3 These are U.S. Patent No. 7,918,8337,918,833 (“the ‘833 patent”), U.S. Patent No. 8,512,297 (“the ‘297 patent”), U.S Patent No. 8,556,864 (“the…“the ‘864 patent”), U.S. Patent No. 8,603,044 (“the ‘044 patent”), and U.S. Patent No. 8,679,069 (“the… the original patent for insulin glargine, U.S. Patent No. 5,656,722 (“the ‘722 patent”), as extended External link to document
0000-00-00 55 Exhibit A , the PTO issued United States Patent No. 7,291,132 (“the ’132 patent”), entitled “Medication Dispensing…diameter.” 100 US Patent No. 7,291,132, abstract. 101 Id.…486 patent, the ’391 patent, the ’211 patent, the ’979 patent, the ’844 patent, the ’105…105 patent, the ’331 patent, the ’008 patent, the ’009 patent, the ’409 patent, and the…“[p]rocess patents, patents claiming packaging, patents claiming metabolites, and patents claiming intermediates External link to document
2018-10-24 73 Memorandum & Order Sanofi’s conduct related to U.S Patent No. 8,556,864 (“the ‘864 Patent”), titled “Drive Mechanisms Suitable…Lilly for patent infringe- ment on two of the formulation patents and two of the pen patents, including…list certain patents in the Orange Book, improperly listing a patent may subject the patent holder to antitrust…of Sanofi’s vial formulation patents – the ‘652 patent and the ‘930 patent.” Id. ¶ 427. The plaintiffs…holder of “formulation” patents covering preparations of insulin, and “pen” patents covering injector pens External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Dow
Baxter
Express Scripts
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.